Madrigal Pharmaceuticals to Present Key Research Findings at EASL Congress
Wednesday, 29 May 2024, 09:16
Madrigal Pharmaceuticals to Present Key Research Findings at EASL Congress
Madrigal Pharmaceuticals is set to reveal multiple research abstracts focusing on Rezdiffra™ and health economics outcomes at the upcoming EASL Congress. The company aims to showcase the latest developments in the treatment of NASH/MASH, shedding light on potential advancements in the field.
The presentation will highlight the company's commitment to advancing liver disease treatment through innovative research and cutting-edge solutions, underlining the importance of continuous progress in the field.
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.